Breaking News

Tweet TWEET

In Hospital-Acquired Pneumonia, Thought Leaders' Opinions and Clinical Data Indicate that Eravacycline Offers Efficacy and

 In Hospital-Acquired Pneumonia, Thought Leaders' Opinions and Clinical Data
   Indicate that Eravacycline Offers Efficacy and Delivery Advantages Over
                         Currently Marketed Therapies

Eravacycline's Competitive Advantages Include Activity Against
Multidrug-Resistant Pathogens and Availability in Interchangeable IV and Oral
Formulations, According to a New Report from Decision Resources

PR Newswire

BURLINGTON, Mass., April 24, 2013

BURLINGTON, Mass., April 24, 2013 /PRNewswire/ --Decision Resources, one of
the world's leading research and advisory firms for pharmaceutical and
healthcare issues, finds that, based on clinical data and the opinions of
interviewed thought leaders, Tetraphase Pharmaceuticals' intravenous and oral
synthetic tetracycline derivative eravacycline will offer competitive
advantages over currently marketed therapies for hospital-acquired pneumonia
(HAP). These advantages include eravacycline's delivery as well as its
activity against multidrug-resistant pathogens, including
methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum
beta-lactamase-producing Enterobacteriaceae. Interviewed thought leaders also
expect Forest/AstraZeneca's ceftazidime/avibactam and Cubist's
ceftolozane/tazobactam to offer improvements in activity against
multidrug-resistant P. aeruginosa, compared to current HAP therapies.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The DecisionBase 2013 report entitled With Growing Rates of Antimicrobial
Resistance, Are Physicians and Hospital Pharmacy Directors Receptive to
Premium-Priced Treatments Targeting Multidrug-Resistant Pathogens?  also 
finds that surveyed U.S. and European infectious disease specialists agree
that clinical trial data demonstrating clinical cure rate in clinically
evaluable patients at test-of-cure visit is a key driver of their prescribing
decisions in HAP. Clinical data and the opinions of interviewed thought
leaders indicate that the current therapies vancomycin and meropenem
(AstraZeneca's Merrem/Meronem, generics) are comparable on this attribute and
have no advantage over sales-leading Pfizer's Zyvox. Additionally, rising
rates of antimicrobial resistance have made frequently used first-line
therapies, such as piperacillin/tazobactam (Pfizer's Zosyn, generics) and
levofloxacin (Johnson & Johnson's Levaquin, Sanofi's Tavanic, Daiichi Sankyo's
Cravit, generics), less effective in clinically curing HAP patients.

"Nearly all trials of antibiotics are powered to demonstrate non-inferiority
between an emerging therapy and an active comparator, and it is unlikely that
results from HAP clinical trials will show significantly better clinical cure
rates for emerging drugs when compared with current therapies," said Decision
Resources Analyst David Holman, Ph.D. "Drug developers may be better served
targeting improvements in pathogen-specific cure rates for emerging HAP
therapies as these attributes may be more easily-attainable targets for
developers looking to differentiate their emerging therapy from marketed
products."

The report also finds that surveyed U.S. hospital pharmacy directors were
generally willing to grant favorable formulary status to new HAP therapies
with improved activity against multidrug-resistant HAP pathogens, particularly
MRSA multidrug-resistant P. aeruginosa, and extended-spectrum beta-lactamase
producing Enterobacteriaceae. Patients with HAP caused by these pathogens have
significantly fewer treatment options and ultimately poorer clinical outcomes.
Responses from surveyed hospital pharmacy directors revealed that therapies
with improved activity against these pathogens could command price premiums to
current treatments.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources

Website: http://decisionresourcesgroup.com
Contact: Christopher Comfort, Decision Resources, 781-993-2597,
ccomfort@dresources.com